B7/CD28 interaction inhibitor 1|635324-72-0|-陌孚医药/Medlife

您当前的位置：

B7/CD28 interaction inhibitor 1

目录号: PL01345 纯度: ≥99%

CAS No. :635324-72-0

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	B7/CD28 interaction inhibitor 1
中文别名	2-(4-氟苯基)-1,6-二氢-6-甲基-4-[3-(三氟甲基)苯基]二吡唑并[3,4-B：3'',4''-D]吡啶-3(2H)-酮;2-(4-氟苯基)-1,6-二氢-6-甲基-4-[3-(三氟甲基)苯基]二吡唑并[3,4-B：3,4-D]吡啶-3(2H)-酮;2-(4-氟苯基)-1,6-二氢-6-甲基-4-[3-(三氟甲基)苯基]二吡唑并[3,4-b:3',4'-d]吡啶-3(2H)-酮
英文名称	B7/CD28 interaction inhibitor 1
英文别名	CTLA-4 inhibitor;2-(4-fluorophenyl)-6-methyl-4-(3-(trifluoromethyl)phenyl)-1,2-dihydrodipyrazolo[3,4-b:3',4'-d]pyridin-3(6H)-one;CTLA-4 - inhibitor;CTLA-4-inhibitor;BCP16856;AK499429;2-(4-fluorophenyl)-6-methyl-4-(3-(trifluoromethyl)phenyl)-1,6-dihydrodipyrazolo[3,4-b:3',4'-d]pyridin-3(2H)-one;4-{6-[(1E,2E)-2-(3-Methylbenzylidene)hydrazino]-2-[2-(2-pyridinyl)ethoxy]-4-pyrimidinyl}morpholine methanesulfona;B7/CD28 interaction inhibitor 1
Cas No.	635324-72-0
分子式	C₂₁H₁₃F₄N₅O
分子量	427.35
包装储存	Powder -20°C 3 years；4°C 2 years

产品详情	B7/CD28 interaction inhibitor 1 (copmound 6b) 是一种有效的 B7.1-CD28 相互作用抑制剂，IC₅₀ 为 50 nM。
生物活性	B7/CD28 interaction inhibitor 1 (copmound 6b) is a potent B7.1-CD28 interaction inhibitor with an IC 50 of 50 nM.
性状	Solid
IC50 & Target[1][2]	IC50: 50 nM (B7.1-CD28 interaction)
体外研究(In Vitro)	Bivalent CTLA4 homodimers bridge bivalent B7.1 homodimers to form an unusually stable signaling complex. Blocking B7/CD28 interactions with monoclonal antibodies or soluble receptors results in immunosuppression and enhanced allograft survival, while B7/CTLA-4 blockade results in enhanced antitumor immune responses. The interaction of co-stimulatory molecules on T cells with B7 molecules on antigen presenting cells plays an important role in the activation of naive T cells. Consequently, agents that disrupt these interactions should have applications in treatment of transplant rejection as well as autoimmune diseases. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Powder -20°C 3 years；4°C 2 years
参考文献	[1]. Green NJ, et al. Structure-activity studies of a series of dipyrazolo[3,4-b:3,4-d]pyridin-3-ones binding to the immune regulatory protein B7.1. Bioorg Med Chem. 2003 Jul 3;11(13):2991-3013.

溶解度数据	In Vitro: DMSO : 62.5 mg/mL (146.25 mM; Need ultrasonic)配制储备液

搜索质检报告(COA)

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品